By A promising new medical treatment may offer a powerful weapon against the most dangerous kind of body fat. In recent early human trials, an experimental injection known as CBL-514 successfully reduced visceral fat, the hazardous deposits that wrap around internal organs deep within the abdomen. Unlike the pinchable fat found just under the skin, visceral fat is closely linked to metabolic dysfunction, insulin resistance, and an increased risk of developing type 2 diabetes. Recent data suggests this specific type of fat may be a more accurate predictor of heart failure than traditional measurements like body mass index.
The study was led by Dr. W. Timothy Garvey from the University of Alabama at Birmingham alongside Yu-Fang Ling of Caliway Biopharmaceuticals. During the phase 2 trials, participants received injections into their lower abdomens every three weeks for up to twelve weeks. The medication works through a selective process called apoptosis, essentially triggering fat cells to self destruct while leaving surrounding healthy tissues completely untouched. This targeted approach allows the drug to eliminate lipids without damaging other cellular structures in the area.
Results from MRI scans revealed a significant difference between those receiving the drug and those given a placebo. Four weeks after finishing the regimen, patients treated with CBL-514 saw an average reduction in visceral fat volume of about 12 percent, whereas those in the control group actually experienced an increase in fat accumulation. While previous tests showed the drug could help slim down subcutaneous fat for cosmetic improvement, researchers emphasize that its ability to reach deeper organ fat is where its true clinical value lies.
Medical experts note that this represents a major leap forward because conventional options like liposuction are unable to touch visceral fat, meaning they provide aesthetic results without improving actual cardiovascular health. Beyond the visible change of a flatter stomach, Dr. Garvey highlighted that the real victory is seen in broader health markers including lowered body weight and improvements in both cholesterol levels and blood pressure. If further trials prove successful, this injection could transform how doctors treat obesity related chronic diseases.
